ClinicalTrials.gg
RecruitingNCT07058857ELITE-STEMIUpdated Jul 10, 2025

The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocardial Infarction - A Single-Centre Randomized Control Trial

An interventional study of Parasym Neuromodulation Device (Treatment Group) and Parasym Neuromodulation Device (Sham Group) in ST Elevation Myocardial Infarction, sponsored by Universitas Diponegoro. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Universitas Diponegoro · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jan 2025, registered Jun 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia — 4 open to participants now, 4 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Indonesia.

Planned enrollment
3rd of 12
100 · median 62
Started
2025
with 2 others
No phase
5 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
5 of 15
Universitas Diponegoro

Among the 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 14th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on echocardiographic parameter in patient with ST-segment Elevation Myocardial Infarction (STEMI) who undergo primart percutaneous coronary intervention (PPCI). It will also learn about the safety of LLTS in such setting. The main questions, it aims to answer are compared with sham control:

Does LLTS could alter left ventricular ejection fraction in patients with STEMI? Does LLTS could alter wall motion score index in patients with STEMI? Does LLTS could alter diastolic dysfunction in patients with STEMI?

Researchers will compare LLTS to sham LLTS control to see if LLTS have benefit in participants with STEMI participants will divided into two group i.e. treatment group vs control (sham/placebo) group..

Both groups undergo transthoracal echocardiographi examination before and after PPCI..

03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • ST-segment elevation myocardial infarction
  • Low level tragus stimulation
  • Left ventricular ejection fraction
  • Wall motion score index
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Onset STEMI less than 12 hours
  • Participant agreed to be included in this study
  • Killip class I - II on presentation
  • SBP >90 mmHg and/or MAP >65 mmHg
  • Sinus rhtyhm

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction, stroke, heart failure with reduce , chronic total occlussion on prior coronary angiography, chronic kidney disease ( \< 30) or on hemodyalisis, , hematology disease, , or other chronic diseases
  • On permanent pacemaker
  • Acute infection
  • Pregnant woman
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Low Level Tragus Stimulation Group

    Participant will undergo low level tragus stimulation using Parasym Device

    Device: Parasym Neuromodulation Device (Treatment Group) · Device: Parasym Neuromodulation Device (Sham Group)

  • Sham comparator
    Sham Control Group

    Participant will have Parasym Device implanted in their tragus without any active stimulation from the device

    Device: Parasym Neuromodulation Device (Treatment Group) · Device: Parasym Neuromodulation Device (Sham Group)

Interventions

  • DeviceParasym Neuromodulation Device (Treatment Group)

    Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device

  • DeviceParasym Neuromodulation Device (Sham Group)

    Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes

06

What researchers measure

Primary outcomes

  1. Left Ventricular Ejection Fraction

    Left Ventricular Ejection Fraction measured by transthoracic echocardiography

    Time frame: Before PPCI, 1 day after PPCI, and 30 days after PPCI

Secondary outcomes

  1. Wall Motion Score Index

    Wall Motion Score Index measured by transthoracic echocardiography

    Time frame: Before PPCI, 1 day after PPCI, and 30 days after PPCI

  2. Diastolic Function

    Diastolic Function measured by transthoracic echocardiography

    Time frame: Before PPCI, 1 day after PPCI, and 30 days after PPCI

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yu L, Huang B, Po SS, Tan T, Wang M, Zhou L, Meng G, Yuan S, Zhou X, Li X, Wang Z, Wang S, Jiang H. Low-Level Tragus Stimulation for the Treatment of Ischemia and Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study. JACC Cardiovasc Interv. 2017 Aug 14;10(15):1511-1520. doi: 10.1016/j.jcin.2017.04.036. PubMed 28797427 ↗
  • Redgrave J, Day D, Leung H, Laud PJ, Ali A, Lindert R, Majid A. Safety and tolerability of Transcutaneous Vagus Nerve stimulation in humans; a systematic review. Brain Stimul. 2018 Nov-Dec;11(6):1225-1238. doi: 10.1016/j.brs.2018.08.010. Epub 2018 Aug 23. PubMed 30217648 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2025, 8 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 8 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 10, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 30, 2025
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07058857
Lead sponsor
Universitas Diponegoro
Responsible party
Sodiqur Rifqi (Principal Investigator; Former of Head of Department of Cardiovascular Medicine Faculty of Medicine Universitas Diponegoro, Universitas Diponegoro) — Principal investigator
First posted
Jul 10, 2025
Start date
Jan 1, 2025
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jul 10, 2025

Study contacts

Leo Deddy Pradipta
Contact
dancingdeagle@gmail.com
+6281316499074

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion